ARCHIVES

Phase II Trial of BIND-014 Shows Anti-Tumor Activity in Q3W Arm

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

It’s Official; Most of NCI NTP contingent Will Move To N.C.

February 22, 1980

Spending Bill Could Give 15% Raise To NIH; Gimmicks Complicate Picture, Veto Looms

November 5, 1999

December Business & Regulatory Report included in this issue.

December 12, 2003

Gene Variant Associated With 44 Percent Cancer Risk Reduction

October 26, 2012

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

July 27, 2001

Groups Urge Passage of Health Care Reform Legislation

January 29, 2010